Our projects are specifically dedicated to proposing alternative treatments for patients suffering from renal diseases while also developing reliable biomarkers and tools to facilitate the diagnosis and assess treatment outcomes to improve the overall management of the patient.
AVEROA’s pipeline is composed of products targeting renal diseases.
Our lead product, Xoanacyl® (AVA1014), received a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on March 27, 2025.
With the LUCIOL project, Averoa is working on a unique treatment (AVA2206) with a new mechanism of action for Renal Lithiasis associated with a companion test (AVA2065).
Renal Diseases Chronic Kidney Diseases (CKD)
Xoanacyl® (AVA1014)
Registration
Ferric Citrate as Coordination Complex
AVA1014 has been licensed from AKEBIA and is already registered and marketed in US under the Brand Name Auryxia® and in Japan under the Brand Name Riona®.
Positive Opinion from CHMP on March 27, 2025
See our press releases issues on April 2, 2025
Renal Lithiasis
Rare renal disease
AVA2206
Late preclinical
Antioxidant
AVEROA signed a research collaboration and license agreement with IdiBell, CIBER and University of Barcelona for the development to develop and exploit the product in the field of kidney and/or metabolic diseases
AVA2206 has been granted with an Orphan Drug Designation (ODD) by the European Medicine Agency (EMA) and the US FDA.
Renal Lithiasis
Rare renal disease
AVA2065
Preclinical
Biomarker
AVEROA signed a research collaboration and license agreement with IdiBell, CIBER and University of Barcelona for the development to develop and exploit the product in the field of kidney and/or metabolic diseases
Co-founder of Advicenne in 2007 and Panntherapi in 2020, he is an expert in the clinical development of innovative products for pharmaceutical and biotech industry. He has conducted many clinical studies and has successfully conducted numerous drug development programs in the field of the central nervous system (CNS) and kidney diseases. In particular, he successfully conducted the proof-of-concept study of the « Blockbuster » duloxetine (Cymbalta, Xeristar, Yentreve), approved by the FDA in 2004. His long history of interactions with the U.S. FDA and European (EMA) regulatory agencies provides Averoa with a strategic regulatory vision that is essential to its development.
